Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
2203 articles about Gilead Sciences, Inc.
-
Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
11/30/2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy ® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients.
-
The agency on Tuesday said it is investigating the “serious risk” of T cell malignancy outcomes, including hospitalization and death, and evaluating the need for potential regulatory action.
-
Gilead Sciences: Breaking Barriers to Breast Cancer Care in Rural Areas
11/21/2023
Claudia Hardy says she's found her life's mission. As director of Community Health Access and Relations for the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham - the only National Cancer Institute-Designated Cancer Center in the state - she brings cancer resources and preventive care to communities in Alabama's Black Belt like the one she grew up in.
-
Kite and Arcellx Announce Expansion in Strategic Partnership
11/15/2023
Kite, a Gilead Company, and Arcellx, Inc., announced that the companies have expanded their existing collaboration, which was originally announced in December 2022.
-
Arcellx and Kite Announce Expansion in Strategic Partnership
11/15/2023
Arcellx, Inc. and Kite, a Gilead Company, announced that the companies have expanded their existing collaboration, which was originally announced in December 2022.
-
Months after the FDA lifted its partial hold on their Phase II multiple myeloma program, Kite and Arcellx are expanding their existing development and commercialization collaboration in the blood cancer space.
-
Gilead Sciences to Present at Upcoming November 2023 Investor Conferences
11/9/2023
Gilead Sciences, Inc. announced that its executives will be speaking at the following investor conferences.
-
Gilead Sciences: Research Scholars Program Scientists Advancing HIV Research
11/9/2023
Gilead Sciences / Dr. Shringar Rao's inquisitive nature and dedication to addressing health inequities drive her eagerness to help advance innovative scientific breakthroughs.
-
The third-quarter growth of Gilead’s HIV, oncology and cell therapy businesses was completely offset by declining COVID-19 and liver disease sales, with revenue flat compared to the same period last year.
-
Gilead Sciences: Advancing Global Health Equity in Tropical Regions
11/7/2023
Gilead Sciences / In the late 1980s, people in Dr. Shyam Sundar's homeland in eastern India were dying by the hundreds of thousands of a debilitating parasitic disease known as visceral leishmaniasis.
-
Gilead Sciences Announces Third Quarter 2023 Financial Results
11/7/2023
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023.
-
A combination of Gilead Sciences’ domvanalimab and Arcus Biosciences’ zimberelimab, along with chemo, has shown an “encouraging” overall response rate in a mid-stage study.
-
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers
11/6/2023
Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate and six-month progression-free survival rate results in a preliminary analysis from Arm A1 of the EDGE-Gastric study.
-
Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
11/3/2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new viral hepatitis data at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, from November 10-14, 2023.
-
Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023
11/2/2023
Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023.
-
New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV
10/20/2023
Gilead Sciences, Inc. presented new data supporting Sunlenca® as an important treatment option for adults with multi-drug resistant HIV who have extensive treatment history.
-
Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities
10/19/2023
Gilead Sciences, Inc. announced new long-term real-world data from the BICSTaR study highlighting the safety and efficacy profile of Biktarvy® as a treatment regimen for a broad range of people with HIV, including those with a prior treatment history or comorbidities.
-
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
10/18/2023
Gilead Sciences, Inc. announced PURPOSE 5, the first Phase 2 clinical trial to evaluate an investigational long-acting HIV prevention option in Europe.
-
Gilead Sciences: Leading With Passion and Purpose: Sandra’s Story
10/17/2023
Gilead Sciences / Many teenagers have some idea of what they want to do for a career - but few are as crystal clear as Sandra Patterson was.
-
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
10/17/2023
Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB) today announced that the companies have entered into a 12-year partnership to advance the research and development of novel antiviral therapies, with an initial focus in Assembly Bio’s established areas of herpesviruses, hepatitis B virus (HBV) and hepatitis D virus (HDV).